INNV · InnovAge Holding Corp. · Stock research

Current Thesis

InnovAge is a post-sanctions PACE turnaround (Programs of All-Inclusive Care for the Elderly) whose fundamental narrative is inflecting while the price has already done most of its recovery work. Census is re-accelerating after years of CMS enrollment freezes, and FY2026 adjusted-EBITDA guidance has been lifted from a $70–75M zone to $85–90M. The catch for a momentum entry today: the stock re-rated +51% off its late-March base (largely multiple expansion), it now sits in a tight mid-range consolidation, and the next company-specific binary the Q4/full-year FY2026 print is roughly eight weeks out. Narrative state reads MATURING, not early-discovery.

Bullish and bearish views on InnovAge Holding Corp.

The model's bull view on InnovAge Holding Corp. (INNV), in brief: Q3 FY2026 revenue $251.9M, +15.5% YoY (reported May 5, 2026), ahead of consensus. The bear view: The recovery is largely priced: shares moved +51% from March 31 to July 6, 2026, with roughly +45.6% of that pure P/S multiple expansion rather than fresh estimate revisions. Both cases follow in full.

Bull Case

• Q3 FY2026 revenue $251.9M, +15.5% YoY (reported May 5, 2026), ahead of consensus.
• Adjusted EBITDA $30.5M and center-level contribution margin $61.0M in the same quarter operating leverage showing up as capitation rates step higher.
• FY2026 guidance raised to $950–975M revenue and $85–90M adjusted EBITDA, up from an earlier $925–950M / $70–75M frame roughly a 20% midpoint bump to EBITDA.
• Census ~8,050 participants across 20 centers as of March 31, 2026, +6.9% YoY enrollment growth has resumed after the multi-year regulatory freeze that gutted the story.
• Q2 FY2026 (reported Feb 3, 2026) already flipped to $11.8M net income versus a $13.5M year-ago loss on $239.7M revenue (+14.7% YoY), evidence the profitability turn is not a one-quarter artifact.
• Jennifer Browne appointed President & COO in May 2026, adding operating depth to the turnaround bench.

Bear Case

• The recovery is largely priced: shares moved +51% from March 31 to July 6, 2026, with roughly +45.6% of that pure P/S multiple expansion rather than fresh estimate revisions.
• Q3 carried a $29.9M GAAP net loss despite the $30.5M adjusted EBITDA a large below-the-line charge keeps reported results lumpy, and GAAP EPS printed near -$0.22 against +$0.078 adjusted.
• Sequential census growth was only +0.5% QoQ; enrollment re-acceleration is regulator- and capacity-gated, so the top-line runway depends on center approvals, not a switch that has been flipped.
• The broad managed-care complex (UNH, HUM, CNC, ELV) is fighting elevated medical-loss ratios through 2025–2026; multiple compression across health-services can bleed into a small-cap capitation model regardless of company-specific execution.
• Regulatory tail risk is structural a single new CMS audit finding or enrollment freeze at any center is a direct census and revenue hit, the exact mechanism that broke the stock in 2021–2022.
• Small float and thin liquidity widen slippage; there is no company catalyst to pull price for ~8 weeks.

Setup & Price Structure

Shares traded ~$11.61 on July 15, 2026 (market cap ~$1.58B), inside a tight $11.06–$11.85 range. The advance from roughly $7.70 in late March was clean and trend-like, capped by a +27% two-week burst into June 29, after which price has coiled just under the $11.85 shelf. This is digestion, not a fresh momentum trigger the impulse leg is behind it and RSI has cooled during the range. A daily push through $11.85 on volume would resume the recovery leg toward new post-sanctions highs and would be the tradable continuation signal; absent that, the name is a mid-range wait. Because the theme is maturing rather than accelerating into a breakout, a fresh entry is better taken on either that breakout or a pullback that builds a higher-low base near support.

Catalyst Calendar (next 30 days)

• No INNV-specific dated catalyst falls inside the next 30 days.
• Sector read-throughs that set the health-services multiple and MLR tone: Elevance ~2026-07-22 (est.), Centene ~2026-07-24 (est.), Humana ~2026-07-30 (est.), CVS/Aetna ~2026-08-06 (est.). Sympathy risk runs both ways.
• Next company binary: Q4/full-year FY2026 results, expected ~2026-09-09 (est.; Q4 FY2025 was reported 2025-09-09). This is where the raised guide gets validated or cut and where full-year census lands versus the 7,900–8,100 ending target.

What Would Change Our Mind

• A weekly close below $10.50 breaks the July consolidation shelf and forfeits the post-sanctions recovery structure; the turnaround thesis goes on hold until a fresh higher-low base forms.
• Secondary conditions that void the read even without that break: a new CMS enrollment freeze or audit sanction at any center; a FY2026 guidance cut or flat-to-negative sequential census at the September print; or the managed-care theme flipping to SATURATED as sector MLR blow-ups compress the whole complex's multiple.

Correlation Notes

This is an idiosyncratic turnaround, not a sector-momentum wave. The large managed-care insurers are under margin pressure and are not breaking out, so there is no cluster confirmation from big MCOs to lean on the move is InnovAge-specific. Primary sensitivities run to Medicaid/dual-eligible policy (state rate-setting, redeterminations) and CMS PACE regulation rather than to rates or the broad tape. Pure-play PACE peers are scarce, so capitation-rate commentary from Medicare Advantage insurers serves as the cleanest proxy for the reimbursement backdrop.